Navigation Links
Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
Date:5/2/2011

LONDON, May 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.  The issued patent covers aspects of Silence's platform of novel, short interfering RNA (siRNA) molecules containing 2'-O-Methyl structures known as AtuRNAi.  Silence's AtuRNAi molecules offer important advantages over conventional siRNA molecules including increased stability and yield, lower manufacturing costs and the absence of toxic metabolites.  Several therapeutics incorporating the company's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence and other industry leaders.

"The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents the latest success in our proactive ongoing intellectual property strategy.  Not only does this milestone offer important protection for our RNAi technology in Japan, but it also provides another critical asset to support our efforts to establish valuable partnerships with leaders in the Japanese pharmaceutical industry," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We believe that this allowance by the Japanese Patent Office coupled with our broad, global protection offered by our core patents will highlight the value of our RNAi therapeutic technology to those Japanese companies with an interest in this exciting area of medicine."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
3. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
4. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
5. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
6. Silence Therapeutics Appoints New Vice President of Research
7. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
(Date:7/30/2014)... Toronto, Canada (PRWEB) July 30, 2014 ... been available in health services research for a ... an upswing in interest regarding the use of ... actual practice conditions. , By combining today’s powerful ... in the digital era, ‘big data’ holds significant ...
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... and Mass Spectrometry Application Note , ... Mass Frontier , Mark R. ... Introduction , ... development. In the early discovery phase, studies are designed to help the ...
... , I. Introduction ... note describes assay conditions for screening GPCR agonists on a ... miniaturized platform results in low cell and reagent consumption, high ... microfluidic assay accesses test compounds from a microtiter plate and ...
... Mike Benway, Larry Simonson and John Ung , ... Applications Laboratory, Hopkinton, Massachusetts, USA , ... "Assay-Ready" plates prepared from compound or library stock plates in real ... to transfer and dilute 0.5μL volumes is a prerequisite for this ...
Cached Biology Technology:Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 2Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 3Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 4Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 5Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 6Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 7Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 8Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 9Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 10HEK293 Calcium Flux Assay 2HEK293 Calcium Flux Assay 3HEK293 Calcium Flux Assay 4HEK293 Calcium Flux Assay 5Dispensing 0.5μL to "Dry" 384 Plates with the Sciclone ALH 2Dispensing 0.5μL to "Dry" 384 Plates with the Sciclone ALH 3
(Date:7/30/2014)... a pledge of $1 million from the Cornelia Cogswell ... Neurobehavioral Biometry Center. , The newly established ... Laboratory to develop a greater breadth and depth of ... accelerating the pace of research to improve human health. ... resource for the Laboratory and its external partners, supporting ...
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
... protein found within nerve cells are a pathological ... identified in the early 1900s by German psychiatrist and ... protein called tau cause it to aggregate in an ... tau protein is involved in the formation of microtubules, ...
... Within many hormone-receptor positive breast cancers lives a subpopulation ... cells with anti-estrogen drugs and you may inadvertently promote ... recently published in the Proceedings of the National ... receptor-negative cells back to a state that can be ...
... unique ways of hunting down a meal using their senses. ... on infrared vision, and owls take advantage of the concave ... possible prey. Leeches have not just one but two distinct ... biologists at the California Institute of Technology (Caltech), their preferred ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells 2Switching senses 2
SAPK/JNK Antibody...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Component in MasterPure™ Purification Kits...
Biology Products: